(MDGL) Madrigal Pharmaceuticals - Ratings and Ratios
Rezdiffra, MASH, Thyroid, Agonist, Treatment
MDGL EPS (Earnings per Share)
MDGL Revenue
Description: MDGL Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The companys lead product, Rezdiffra, is a liver-directed thyroid hormone receptor beta agonist designed to treat MASH, a condition characterized by inflammation and fat accumulation in the liver.
To evaluate the companys performance, we can examine key performance indicators (KPIs) such as revenue growth, pipeline progress, and clinical trial results. As a biotech company, Madrigals success is heavily dependent on the efficacy and market adoption of Rezdiffra. Key metrics to watch include the drugs sales trajectory, patient enrollment rates, and any upcoming clinical trial readouts.
From a financial perspective, Madrigals market capitalization stands at approximately $6.9 billion, indicating a significant investor interest in the companys prospects. The absence of a price-to-earnings (P/E) ratio is not surprising, given that the company is likely still in a growth phase and not yet profitable, as indicated by the negative return on equity (RoE) of -50.54%. Investors should monitor the companys cash burn rate, research and development expenses, and any potential partnerships or collaborations that could impact its financial trajectory.
To further assess Madrigals potential, its essential to consider the competitive landscape of the MASH treatment market, as well as the companys intellectual property position and regulatory outlook. A thorough analysis of these factors can help investors better understand the companys growth prospects and potential risks, ultimately informing their investment decisions.
MDGL Stock Overview
| Market Cap in USD | 9,519m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2007-02-06 |
MDGL Stock Ratings
| Growth Rating | 77.0% |
| Fundamental | 30.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 50.9% |
| Analyst Rating | 4.47 of 5 |
MDGL Dividends
Currently no dividends paidMDGL Growth Ratios
| Growth Correlation 3m | 90% |
| Growth Correlation 12m | 40.4% |
| Growth Correlation 5y | 74.8% |
| CAGR 5y | 90.33% |
| CAGR/Max DD 3y | 1.47 |
| CAGR/Mean DD 3y | 5.32 |
| Sharpe Ratio 12m | -0.44 |
| Alpha | 0.38 |
| Beta | 0.321 |
| Volatility | 49.55% |
| Current Volume | 286.3k |
| Average Volume 20d | 304.2k |
| Stop Loss | 400 (-4.2%) |
| Signal | -0.71 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-281.9m TTM) > 0 and > 6% of Revenue (6% = 30.9m TTM) |
| FCFTA -0.45 (>2.0%) and ΔFCFTA -15.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 156.5% (prev 6273 %; Δ -6117 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.30 (>3.0%) and CFO -307.4m <= Net Income -281.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (22.2m) change vs 12m ago 3.76% (target <= -2.0% for YES) |
| Gross Margin 96.01% (prev 91.25%; Δ 4.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.75% (prev 1.40%; Δ 47.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -19.52 (EBITDA TTM -266.7m / Interest Expense TTM 13.7m) >= 6 (WARN >= 3) |
Altman Z'' -8.95
| (A) 0.79 = (Total Current Assets 1.00b - Total Current Liabilities 196.5m) / Total Assets 1.02b |
| (B) -1.89 = Retained Earnings (Balance) -1.92b / Total Assets 1.02b |
| warn (B) unusual magnitude: -1.89 — check mapping/units |
| (C) -0.25 = EBIT TTM -268.2m / Avg Total Assets 1.06b |
| (D) -6.00 = Book Value of Equity -1.92b / Total Liabilities 319.4m |
| Total Rating: -8.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.66
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -5.17% = -2.59 |
| 3. FCF Margin -88.65% = -7.50 |
| 4. Debt/Equity 0.17 = 2.49 |
| 5. Debt/Ebitda -0.45 = -2.50 |
| 6. ROIC - WACC (= -38.60)% = -12.50 |
| 7. RoE -38.38% = -2.50 |
| 8. Rev. Trend 90.26% = 6.77 |
| 9. EPS Trend 49.74% = 2.49 |
What is the price of MDGL shares?
Over the past week, the price has changed by -2.95%, over one month by +6.64%, over three months by +49.30% and over the past year by +78.88%.
Is Madrigal Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MDGL is around 606.82 USD . This means that MDGL is currently undervalued and has a potential upside of +45.37% (Margin of Safety).
Is MDGL a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 1
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the MDGL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 481.9 | 15.4% |
| Analysts Target Price | 481.9 | 15.4% |
| ValueRay Target Price | 668.6 | 60.2% |
Last update: 2025-09-18 04:38
MDGL Fundamental Data Overview
CCE Cash And Equivalents = 802.0m USD (Cash And Short Term Investments, last quarter)
P/S = 18.4629
P/B = 13.6765
Beta = -1.025
Revenue TTM = 515.5m USD
EBIT TTM = -268.2m USD
EBITDA TTM = -266.7m USD
Long Term Debt = 118.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.05m USD (from shortTermDebt, last quarter)
Debt = 119.4m USD (Calculated: Short Term 1.05m + Long Term 118.4m)
Net Debt = -67.2m USD (from netDebt column, last quarter)
Enterprise Value = 8.84b USD (9.52b + Debt 119.4m - CCE 802.0m)
Interest Coverage Ratio = -19.52 (Ebit TTM -268.2m / Interest Expense TTM 13.7m)
FCF Yield = -5.17% (FCF TTM -457.0m / Enterprise Value 8.84b)
FCF Margin = -88.65% (FCF TTM -457.0m / Revenue TTM 515.5m)
Net Margin = -54.68% (Net Income TTM -281.9m / Revenue TTM 515.5m)
Gross Margin = 96.01% ((Revenue TTM 515.5m - Cost of Revenue TTM 20.6m) / Revenue TTM)
Tobins Q-Ratio = -4.61 (set to none) (Enterprise Value 8.84b / Book Value Of Equity -1.92b)
Interest Expense / Debt = 2.73% (Interest Expense 3.26m / Debt 119.4m)
Taxrate = 21.0% (US default)
NOPAT = -268.2m (EBIT -268.2m, no tax applied on loss)
Current Ratio = 5.11 (Total Current Assets 1.00b / Total Current Liabilities 196.5m)
Debt / Equity = 0.17 (Debt 119.4m / last Quarter total Stockholder Equity 696.0m)
Debt / EBITDA = -0.45 (Net Debt -67.2m / EBITDA -266.7m)
Debt / FCF = -0.26 (Debt 119.4m / FCF TTM -457.0m)
Total Stockholder Equity = 734.5m (last 4 quarters mean)
RoA = -27.76% (Net Income -281.9m, Total Assets 1.02b )
RoE = -38.38% (Net Income TTM -281.9m / Total Stockholder Equity 734.5m)
RoCE = -31.44% (Ebit -268.2m / (Equity 734.5m + L.T.Debt 118.4m))
RoIC = -31.46% (NOPAT -268.2m / Invested Capital 852.3m)
WACC = 7.14% (E(9.52b)/V(9.64b) * Re(7.20%)) + (D(119.4m)/V(9.64b) * Rd(2.73%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 2.40%
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -457.0m)
EPS Correlation: 49.74 | EPS CAGR: 26.66% | SUE: 1.24 | # QB: 5
Revenue Correlation: 90.26 | Revenue CAGR: 2196 % | SUE: 4.0 | # QB: 2
Additional Sources for MDGL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle